Cargando…
Use of DNA‐alkylating pyrrole‐imidazole polyamides for anti‐cancer drug sensitivity screening in pancreatic ductal adenocarcinoma
BACKGROUND: Activating mutations of the KRAS occurs in >90% of pancreatic ductal adenocarcinoma (PDAC) cases. However, direct pharmacological targeting of the activated KRAS protein has been challenging. We previously reported that KR12, a DNA‐alkylating pyrrole‐imidazole polyamide designed to re...
Autores principales: | Tsujimoto, Akiko, Matsuo, Niina, Lai, Xiaoyi, Inoue, Takahiro, Yoda, Hiroyuki, Lin, Jason, Shinozaki, Yoshinao, Watanabe, Takayoshi, Koshikawa, Nobuko, Takatori, Atsushi, Nagase, Hiroki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028039/ https://www.ncbi.nlm.nih.gov/pubmed/36262061 http://dx.doi.org/10.1002/cam4.5359 |
Ejemplares similares
-
Targeting the mutant PIK3CA gene by DNA‐alkylating pyrrole‐imidazole polyamide in cervical cancer
por: Krishnamurthy, Sakthisri, et al.
Publicado: (2021) -
Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides
por: Ota, Yoko, et al.
Publicado: (2021) -
Estimating genome-wide off-target effects for pyrrole-imidazole polyamide binding by a pathway-based expression profiling approach
por: Lin, Jason, et al.
Publicado: (2019) -
Identification of Binding Targets of a Pyrrole-Imidazole Polyamide KR12 in the LS180 Colorectal Cancer Genome
por: Lin, Jason, et al.
Publicado: (2016) -
Suppression of non‐small‐cell lung cancer A549 tumor growth by an mtDNA mutation‐targeting pyrrole‐imidazole polyamide‐triphenylphosphonium and a senolytic drug
por: Tsuji, Kohei, et al.
Publicado: (2022)